Blasenkarzinom – Update: Was gab es neues auf dem Jahreskongress 2010 der Deutschen Gesellschaft für Urologie in Düsseldorf?

Roman Nawroth(TUM Klinikum), S. Füssel(German Cancer Research Center), Axel S. Merseburger(Universitäres Kinderwunschzentrum Lübeck), P. Olbert(Philipps University of Marburg), Ruth Knüchel(Universitätsklinikum Aachen), Robert Stöhr(Friedrich-Alexander-Universität Erlangen-Nürnberg), Arndt Hartmann(Universitätsklinikum Erlangen), Margitta Retz(Arbeitsgemeinschaft Urologische Onkologie)
RWTH Publications (RWTH Aachen)
February 1, 2011
Cited by 1

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2017|1.4k
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a<i>BRCA1</i>or<i>BRCA2</i>Gene Alteration
|Journal of Clinical Oncology|2020|676